Periacetabular osteotomy (PAO) is a demanding procedure that puts patients at risk for potentially significant blood loss, and blood transfusions. Avoidance of transfusions in otherwise healthy young patients is important. This project was designed to study the effectiveness of our blood conservation efforts.

178 consecutive PAOs performed in one hospital by one surgeon (RFS) from 2008 to 2016 were reviewed retrospectively. PAO's were performed in other hospitals, too, but a majority were from the study group hospital. Data were collected from digitalized patient office charts and hospital electronic medical records. Collected data were analyzed for categorical associations between blood loss, demographic data, and transfusion risks.

Over the past 27 months, the transfusion rate in 63 consecutive patients has been reduced to Zero. Discontinuation of drains, use of TXA, spinal anesthesia, reducing trigger for transfusion to Hgb of <7, cell saver use in all cases, and careful intraop coagulation, among others, have been incrementally incorporated. The overall transfusion rate was 10.7% for all patients. In the early years of this study, prior to adoption of all of these blood conservation measures, the transfusion rate was 12.5%. Over the past four years the transfusion rate was 1.5%. Over the last two years it has been zero.

There is little data specifically regarding transfusion rates in PAOs but this study establishes that an aggressive approach to blood saving techniques and limitation of bleeding can reduce the risk of transfusion to virtually zero in this population of mostly young patients.

Autologous drains are used frequently in total knee replacement surgery but not in total hip replacement surgery (THR). Previous studies have shown that these drains are not cost effective in THR surgery. We studied the effectiveness of autologous drains in THR surgery compared with normal suction drains.

All the patients had an uncemented hip. The Bellovac®A.B.T (Astra) autologous drainage system was used. Patients using the drains were studied prospectively and the volume of drainage, volume of autotransfusion, amount of homologous blood transfused and the hospital stay were all recorded. A group of patients who had normal suction drains were studied retrospectively to determine the transfusion rate and hospital stay using these drains.

In the group using standard suction drains there were 43 patients with a mean age of 72. The mean drainage was 641 ml (Range 500 – 1070). 10 patients out of 43 had a transfusion (Transfusion rate 23%). A total of 21 units of blood were used. The mean hospital stay was 14 nights. In the group using autologous drains there were 38 patients with a mean age of 67. The mean drainage was 703 ml (Range 200 – 1700), and of this the mean volume of blood that was given back to the patient was 445 ml (Range 50 – 1050). 2 out of 38 patients have required a blood transfusion, a transfusion rate of 5 % . This reduction in transfusion rate is significant (p< 0.005). The mean hospital stay was 9 nights. The difference in the hospital stay was not statistically significant.

Using the autologous drainage system in uncemented total hip replacement surgery reduces the need for a homologous blood transfusion. It is simple and easy to use and avoids the complications of a blood transfusion. It was also found to be cost effective.

Rivaroxiban is a factor Xa inhibitor and is a newer oral alternative for thromboprophylaxis after joint replacements. Its major advantage is its oral administration and hence better patient compliance. However there are some doubts about its efficacy compared to dalteparin/heparin. We have recently changed over from using dalteparin injections to rivaroxiban tablets for thromboprophylaxis after hip replacements. We assessed our results to find efficacy and specificity of its action in patients undergoing THR.

504 patients underwent hip replacement in last 2 years. 316 were treated with dalteparin injections (fragmin) for thromboprophylaxis while 189 patients were treated with oral rivaroxiban for 35 days after their hip replacement.

Average haemoglobin drop at 24 hours postop was 2.79 in Rivaroxiban group compared to 3. 10 in dalteparin group. 19 patients (of 189 i.e. 10.05%) required postop blood transfusion in rivaroxiban group as against 60 (of 315 i.e. 19.04%) in Dalteparin group. This difference was statistically significant. Incidence of DVT was no different in either groups, but the number of patients was too small to compare this.

Rivaroxiban appears to be more specific in its action and our results suggest a significant reduction in postop blood transfusion following hip replacements without any increase in rate of Deep Vein Thrombosis. We would like to present our findings and discuss role of oral thromboprophylaxis after joint replacements.

In this study we evaluate whether a single dose of intravenous Tranexamic acid on wound closure leads to a significant reduction in both blood loss and transfusion rates following primary total knee arthroplasty.

We recruited patients prospectively who were undergoing primary total knee replacement over an 11 month period from 1^st January to 12^th November 2009. Patients were divided into two groups. Group A were given a single 500mg dose of intravenous Tranexamic acid on wound closure and group B did not receive Tranexamic acid. 282 were eligible for the study, but 59 were excluded. There were 81 patients in group A and 142 patients in group B. The group populations were matched for age, sex, body mass index, ASA (American Society of Anaesthesiologists) grade, and pre-operative haemoglobin. The average post-operative haemoglobin drop was 1.76 g/dl in group A, compared with 2.37 g/dl in group B. The transfusion rate was 1.2% in group A, compared with 12% in group B.

After taking into account the possible confounding factors, post-operative haemoglobin drop (p< 0.001), transfusion rate (p=0.026) and length of hospital stay (p=0.014) were shown to have a significant difference between the two groups (using multiple linear, logistic or ordinal logistic regression). From our results, the use of 500mg of intravenous tranexamic acid during closure of the wound during total knee replacement significantly reduces the post-operative haemoglobin drop, reducing the need for transfusion, and may reduce the length of hospital stay.

The purpose of this prospective randomized study was to compare the visible, hidden, total blood loss and postoperative haemodynamic change of subcutaneous and intra-articular indwelling closed suction drainage method after total knee arthroplasty (TKA). Patients with primary osteoarthritis, who underwent unilateral TKA were enrolled; Group A with subcutaneous (n=78) and group B with intra-articular (n=79) indwelling closed suction drainage method. Total blood loss, visible blood loss, internal blood loss, postop (day 1), 5^th, 10^th day hemoglobin, hematocrit levels were compared. Allogenic blood transfusion rate and complications related to soft tissue hematoma formation were additionally compared. Subcutaneous indwelling closed suction drainage method reduced both the visible blood loss and total blood loss (hemovac drainage + internal blood loss) thus decreasing the rate of allogenic transfusion. Although the minor complications such as the incidence of bullae formation and the ecchymosis were higher in the subcutaneous indwelling group, the functional outcome at postoperative 2 year did not demonstrate difference from intra-articular drainage group.

Introduction: We present the results of a prospective study of the blood transfusion requirements in patients undergoing a Bernese periacetabular osteotomy (PAO) with the use of an intra-operative cell-saver and without pre-donated blood. These data were compared with an earlier audit of patients who underwent this procedure without use of a cell saver.

Material and Methods: A cohort of 50 patients (56 hips) underwent a PAO for hip dysplasia between December 2006 and November 2008 performed by the senior author. The average age was 29 years (17–51) and there were 38 females and 12 males. The average weight was 69.96 kg (46–110) and the mean duration of operation was 136 minutes (100–240). A cell saver (Fresenius-Hemocare, Germany) was used intra-operatively for this cohort. Pre-operative Hb, post-operative Hb taken the day after surgery and any units transfused were documented. A post-operative transfusion policy was adopted where a haemoglobin (Hb) concentration of < 7.5 g/dl was an indication for transfusion or where a patient was sufficiently symptomatic

Results: The mean pre-operative Hb was 13.60 g/dl (10.8–15.9) and the mean post-operative Hb was 9.91 g/dl (6.4–11.8). Overall 4 patients received post-operative allogenic blood transfusion; 3 patients receiving one unit and one patient receiving 2 units. No patients received intra-operative allogenic blood.

Conclusion: Compared to our previous audit, the use of the cell saver resulted in an improvement in the mean post-operative Hb, (9.2 g/dl compared to 8.0 g/dl). The transfusion rate was also reduced (7.27% compared to 10.8%)..

Introduction: There is a general conception in the orthopaedic community that blood loss/transfusion rate in hip resurfacing procedures is greater than that conventional Total Hip Arthroplasty (THA). The theoretical basis is that uncemented procedures leave large bleeding bone surfaces and that resurfacing arthroplasty needs larger incisions, greater exposure and more extensive soft tissue releases. Although this theory has gained informal

Acceptance in orthopaedic practice, there is little evidence in the literature to support this.

Background The purpose of this study was to determine the actual blood loss and transfusion rate (including hidden blood loss) in a consecutive cohort of patients undergoing hip re-surfacing by a single surgeon using the Articular Surface Replacement (ASR – DePuy).

Materials and Methods: The cohort consisted of 58 patients who were followed prospectively. All patients underwent a standardized surgical procedure performed by one senior surgeon. Hypotensive anaesthesia was used in all cases and surgery was via a standard posterior approach. Drains were not routinely placed, but if used, were removed within 24 hours. Low Molecular Weight Heparin was given 24 hours post procedure until discharge. Surgical blood loss was calculated in a standard fashion (suction volume plus swab weight). Drain volume (if used) was added after removal at 24 hours. Unseen loss of blood in soft tissues, joint space, as well as loss due to haemolysis, is calculated by the modified formula of Kallos¹:

\batchmode \documentclass[fleqn,10pt,legalpaper]{article} \usepackage{amssymb} \usepackage{amsfonts} \usepackage{amsmath} \pagestyle{empty} \begin{document} \[MABL=\ EBV\ x\ (\underline{Hct\ pt\ -\ Hct\ min})\] \end{document}

Hct pt, Where is

MABL = Maximum allowable blood loss

EBV =Estimated blood volume, 70 ml/kg

Hct pt= Pre operative haematocrit of patient

Hct min=Minimum allowable haematocrit

This was modified to

\batchmode \documentclass[fleqn,10pt,legalpaper]{article} \usepackage{amssymb} \usepackage{amsfonts} \usepackage{amsmath} \pagestyle{empty} \begin{document} \(ABL=\ EBV\ {\times}\ \frac{(Hct\ pre\ op\ {-}\ Hct\ post\ opD2)}{Hct\ pre\ op}\) \end{document} where is

ABL= Actual blood loss, Unseen loss = ABL – Visible loss (Loss in OT + Drain)

Results: 58 Patients undergoing ASR, the aeitology was Osteoarthritis in 50 Patients, Dysplasia in 3, Inflammatory Arthritis in 1 and in 1 patient the aetiology was arthrosis secondary to trauma. The average blood loss during the procedure was 221 mls. After 24 hours this had risen to 377 ml, Mean Unseen blood loss was 787.6 ml, Mean Total actual blood loss was 1385.6 ml. There was a mean drop in haemoglobin of 3.6 g/dl and mean drop of Hematocrit was 10.33%. Only 3 patients required blood transfusion.

Conclusion: The mean blood loss in this study was 598 ml and actual blood loss was 1385.60. This is considerably lower than expected for resurfacing arthroplasty and results in a low transfusion rate of only 5% patients undergoing the procedure. Meticulous haemostasis combined with hypotensive anaesthesia reduced the perioperative blood loss and transfusion rate

Aims

Total hip arthroplasty (THA) using the direct anterior approach (DAA) is undertaken with the patient in the supine position, creating an opportunity to replace both hips under one anaesthetic. Few studies have reported simultaneous bilateral DAA-THA. The aim of this study was to characterize a cohort of patients selected for this technique by a single, high-volume arthroplasty surgeon and to investigate their early postoperative clinical outcomes.

Tranexamic acid (TXA), an inhibitor of fibrinolysis, reduces blood loss after total knee arthroplasty. However, its effect on minimally invasive total hip arthroplasty (THA) is not clear. We performed a prospective, randomised double-blind study to evaluate the effect of two intravenous injections of TXA on blood loss in patients undergoing minimally invasive THA.

In total, 60 patients (35 women and 25 men with a mean age of 58.1 years; 17 to 84) who underwent unilateral minimally invasive uncemented THA were randomly divided into the study group (30 patients, 20 women and ten men with a mean age of 56.5 years; 17 to 79) that received two intravenous injections 1 g of TXA pre- and post-operatively (TXA group), and a placebo group (30 patients, 15 women and 15 men with a mean age of 59.5 years; 23 to 84). We compared the peri-operative blood loss of the two groups. Actual blood loss was calculated from the maximum reduction in the level of haemoglobin. All patients were followed clinically for the presence of venous thromboembolism.

The TXA group had a lower mean intra-operative blood loss of 441 ml (150 to 800) versus 615 ml (50 to 1580) in the placebo (p = 0.044), lower mean post-operative blood loss (285 ml (120 to 570) versus 392 ml (126 to 660) (p = 0.002), lower mean total blood loss (1070 ml (688 to 1478) versus 1337 ml (495 to 2238) (p = 0.004) and lower requirement for transfusion (p = 0.021). No patients in either group had symptoms of venous thromboembolism or wound complications.

This prospective, randomised controlled study showed that a regimen of two intravenous injections of 1 g TXA is effective for blood conservation after minimally invasive THA.

Cite this article: Bone Joint J 2015;97-B:905–10.

Purpose. Transfusion rates after primary total hip has been reported up to 39.2%. The purpose of our study was to evaluate the efficacy of TXA in minimizing risk of allogeneic blood transfusion after primary total hip and hip resurfacing arthroplasty. Method. Retrospective data on a cohort of 88 patients undergoing total hip arthroplasty and 44 who undergoing hip resurfacing arthroplasty who received a single pre-operative bolus of 1g TXA was compared with a control group matched for starting haemoglobin (Hg), body mass index (BMI), age, gender, blood loss, surgical time, and surgeon. All procedures were completed at a single institution with standardized post-operative care. Endpoints included allogeneic blood transfusion rate, post operative day one Hg, and overall Hg decrease. Results. Transfusion rate among the total hip TXA group was 5.7% and among control patients 22.7% (p=0.001). Transfusion rates among resurfacing patients showed no statistical difference between the treatment group and matched controls. Mean overall haemoglobin decrease was found to be significantly lower in the TXA treatment groups for both total hip and hip resurfacing arthroplasty (p<0.0001 and p=0.01 respectively). Patients who received TXA and allogeneic blood transfusion were found to have a significantly lower pre-operative Hg versus transfusion negative TXA treated patients (113.7 g/dL and 141.5 g/dL respectively). Conclusion. We have shown TXA use in primary total hip arthroplasty significantly decreases allogeneic blood transfusion rate. TXA use in hip resurfacing arthroplasty failed to show significant difference in transfusion rate yet calculated blood loss was less. Patients presenting with low pre-operative Hb remain high risk for allogeneic blood transfusion despite TXA treatment

Background. There are multiple documented advantages of undertaking total knee arthroplasty (TKA) without tourniquet, however, increased rates of blood loss and transfusion are often cited as contraindications to this approach. The aim of this study was to examine the effect of intra-operative TA administration on blood loss and transfusion rates in TKA without pneumatic tourniquet, using Rivaroxaban as thrombo-embolic prophylaxis. Method. 120 patients split into two continuous data sets, (A+B), underwent TKA without application of above knee tourniquet, receiving a post operative dose of oral Rivaroxaban within 8 hours. Group B patients received an intra-operative dose of 1 gram of Tranexamic Acid intravenously before the first cut, whilst those in group A did not. Haemoglobin and haematocrit levels were recorded peri-operatively. A revised Gross formula was used to calculate blood loss. Four patients were excluded from the study for incomplete data. Results. 58 patients (M34F24) in Group A, average age 6, had a mean haemoglobin drop of 33gram/litre, haematocrit drop of 0.097litre/litre (9.7%), with an average calculated blood loss of 1393ml. 58 (M34, F24) patients in group B, average age 67, had a haemoglobin drop of 25.2gram/litre, haemotocrit drop of 0.076litre/litre (7.6%) with an average calculated blood loss of1079ml. Thus Group A patients were seen to sustain significantly more blood loss without TA administration, with a 29.1% larger calculated blood loss, a 25.5% larger drop in haemoglobin and a 27.6% larger fall in haematocrit. Transfusion rate was 5.2% (3 patients) per group. Conclusion. TA was shown to be effective in reducing blood loss in TKA without tourniquet using Rivaroxaban. Transfusion rates of 5.2% across both groups is close to 1/10th of the transfusion rate reported for some major studies of TKA using Rivaroxaban with tourniquet application, and 1/8th of the transfusion rate in studies of TKA with administration of TA and use of tourniquet. Level of Evidence. Level-III. The authors report there are no relevant disclosures to make. Ethical approval was granted for the study

Aim: Allogenic blood transfusion rate and related factors, in a cohort of 78 consecutive primary total knee replacements without patellar substitution (TKR) between January 2007 and December 2008 in the Hospital Axarquía (Málaga; Spain). Patients and Methods: All patients were diagnosed of primary knee osteoarthritis. Along 2007 (group I) they were admitted in the previous day to a TKR and discharged following surgeon criteria. In 2008 (group II), patients were admitted on the day surgery, underwent a cemented TKR and were discharged following an objective clinical pathway. Variables: age, sex, comorbidities, previous surgery, length of stay (LOS), Ahlbäck classification, prosthesis fixation, surgery time, pre- and postoperative Hb, blood transfusion, readmission at the first 30-days and complications in the first postoperative year. Statistical analysis were carried out by the software SPSS 11.0. Results: Group I: Mean age 69 yrs (52–80), gender 1:2,4. 89,7% Ahlbäck 3 and 4. 44% hybrid implants. Mean surgery time 100 minutes. LOS 13,3 days (7–28). Mean preop Hb 12,9 g/dl (10–16,5) and Hb at discharge 10,27 g/dl (8,4–13,1). Transfusion rate 14,63%. There were a 25% of complications in the first year. Group II: Mean age 69,7 yrs (54–84), gender 1:1,3. 94,2% Ahlbäck 3 and 4. 8 % of hybrid implants. Mean surgery time 112 minutes. LOS 3,78 days (2–8). Mean preop Hb 13,24 g/dl (11–15,8) and Hb level at discharge 10,15 g/dl (8–13,5). Transfusion rate was 10,8%. There were a 8,1% of complications in the first year. None of complications was related with a tisular oxigenation deficit, nor there were readmissions within the first postoperative month. Transfusion rates difference were not statistically significative. Statistically associated variables were preoperative Hb level < 12,5 g/dl (p=0,001), and postoperative Hb level at 24 hr. < 9,5 g/dl (p=0,017). Discussion: Allogenic transfusion rates reported in our country without specific blood saving measures ranged from 30% to 46%. Several strategies have been developed to reduce blood transfusions and its complications. The golden rule is the appropriateness of the transfusion, attending clinical and analytical parameters based on guidelines. Our study suggest the best strategy is an appropriate transfusion indication, thus obtaining a transfusion rate low enough to made expensive pre-operative autologous blood predonation and peri-operative blood salvage programs unnecessary. Postoperative hemoglobin level predictive blood transfusion enables a safe and saving time hospital discharge. Conclusions: The main factors predicting the need for postoperative blood transfusion after TKA are preoperative hemoglobin levels and postoperative hemoglobin levels at 24 hr. Short time results are improved when surgeons use transfusion guidelines with less transfusional morbidity and cost-saving without compromising patients’ safe and outcomes

Introduction. Perioperative hospital adverse events are an issue that every surgeon endeavors to avoid and minimize as much as possible. Even “minor events” such as fever or tachycardia may lead to significant costs due to workup tests, inter-consultations, and/or increased hospital stay. The objective of this study was compare perioperative outcomes (hospital length of stay [LOS], discharge disposition), rates of in-hospital adverse events and transfusion, and postoperative readmission and reoperation rates for simultaneous and staged bilateral direct anterior total hip arthroplasty (DA-THA) patients. Methods. A retrospective chart review was conducted on a consecutive series of 411 primary bilateral DA-THAs performed between 2010 and 2016 at a single institution by two fellowship trained surgeons. These were categorized as: (1) simultaneous (same anesthesia, n=122) and (2) staged (different hospitalizations, n=289). The mean time between staged surgeries was 468 days (± 414 days). Baseline patient demographics as well as hospital LOS, discharge disposition (home vs. other), hospital adverse events (i.e., nausea, vomiting, tachycardia, fever, confusion, pulmonary embolism, etc.), blood transfusions, and unplanned hospital readmissions and reoperations within 90 days were collected. Groups were compared using independent –tests, Fisher's exact test, and Pearson Chi-Square. Results. Overall, the baseline patient characteristics of the simultaneous DA-THA group had significantly younger patients, a higher proportion of males, and twice the proportion of patients with ASA 1 status compared with the staged DA-THA group. The simultaneous group showed statistically significant longer LOS (2.6 vs. 1.8 days, p<0.001) and an increased proportion of patients discharged to an extended care facility (23% vs. 5.9%, p<0.001). The overall rate of hospital adverse events in the series was 136/411 (33.1%), with a higher rate in the simultaneous DA-THA patients (54.1% vs. 24.2%, p<0.001). Transfusion rate was higher in the simultaneous DA-THA group (45.9%) compared to the staged group (6.9%) (p<0.001). There were no readmissions and a single reoperation in the staged DA-THA group at 90 days postoperative. Conclusion. These data show that bilateral DA-THAs performed in a staged fashion, rather than simultaneously, have a shorter hospital LOS and decreased rates of hospital adverse events and transfusions

Background. Intraoperative blood loss is a known potential complication of total knee arthroplasty (TKA). Tranexamic acid (TXA) has been shown to reduce intraoperative blood loss and postoperative transfusion in patients undergoing TKA. While there are numerous studies demonstrating the efficacy of intravenous and topical TXA in patients undergoing TKA, there are comparatively few demonstrating the effectiveness and appropriate dosing recommendations of oral formulations. Methods. A retrospective cohort study of 2230 TKA procedures at a single institution identified 3 treatment cohorts: patients undergoing TKA without the use of TXA (no-OTA, n=968), patients undergoing TKA with administration of a single-dose of oral TXA (single-dose OTA, n=164), and patients undergoing TKR with administration of preoperative and postoperative oral TXA (two-dose OTA, n=1098). The primary outcome was transfusion rate. Secondary outcomes included maximum postoperative decline in hemoglobin, number of blood units transfused, length of hospital stay, total drain output, cell salvage volume, and operating room time. Results. Transfusion rates decreased from 24.1% in the no-OTA group to 13.6% in the single-dose OTA group (p<0.001) and 11.1% in the two-dose OTA group (p<0.001), with no significant difference in transfusion rates between single- and two-dose OTA groups (p=0.357). Operating room time was reduced from 154 minutes in the no-OTA group to 144 minutes in the one-dose OTA group and 144 minutes in the two-dose OTA group (p<0.01). Additionally, maximum postoperative decline in hemoglobin was reduced from 4.3 g/dL in the no-OTA group to 3.5 g/dL in the single-dose OTA group (p<0.01) and 3.4 g/dL in the two-dose OTA group (p<0.01), without a significant difference between the single- and two-dose regimens (p=0.233). Conclusions. OTA reduces transfusions and operating room time, with the potential advantages of greater ease of administration and improved cost effectiveness relative to other routes of administration. Further study such as a randomized clinical trial is needed to verify the effectiveness of OTA and further optimize dosing regimens in the TKA setting. Level of Evidence. Therapeutic Level III

Anterior supine intermuscular total hip arthroplasty (ASI-THA) has emerged as a muscle sparing, less-invasive procedure. The anterior interval is both intermuscular and internervous, providing the advantages of little or no muscle dissection, and a true minimally invasive alternative. It is versatile, with reported use expanding beyond the primary realm to revision and resurfacing THA as well as treatment of acute fracture in elderly patients, who due to their diminished regenerative capacity may benefit more from the muscle-sparing nature of the anterior approach. The ASI approach involves the use of a standard radiolucent operative table with the table extender at the foot of the bed and the patient supine. Fluoroscopy is used in every case. A table-mounted femur elevator is utilised to facilitate femoral preparation. A retrospective review identified 824 patients undergoing 934 consecutive primary ASI-THA performed between January 2007 and December 2010. Age averaged 63.2 years (27‐92), BMI averaged 29.9 kg/m2 (16.9–59.2). Gender was 49% males and 51% females. Stem types were short in 82% and standard length in 18%. Follow-up averaged 23.1 months (1‐73). Operative time averaged 63.1 minutes (29‐143). Blood loss averaged 145.3 mL (25‐1000). Transfusion rate was 3.3% (30 of 914) in single procedures and 80% (8 of 10) in simultaneous bilateral procedures. Length of stay averaged 1.7 days (1‐12). Intraoperatively there were 3 calcar cracks and 1 canal perforation treated with cerclage cables. There were 6 wound complications requiring debridement. Four hips had significant lateral femoral cutaneous nerve parathesias not resolved at 12 months. One femoral nerve palsy occurred. At up to 73 months follow-up there have been 21 revisions (2.2%): 2 infection, 1 malpositioned cup corrected same day, 5 metal complications, 2 dislocations, 2 loose cups with one requiring concomitant stem revision secondary to inability to disarticulate trunnion, 1 femoral subsidence and 8 periprosthetic femoral fractures. Primary THA can be safely performed utilising this muscle-sparing approach. We did not see an alarmingly high rate of complications. Instead, rapid recovery and quick return to function were observed. ASI-THA appears to be safe. The recovery advantage utilising this surgical approach is irrefutable. There are complications, most notably periprosthetic femur fracture. The rate, however, appears to be low and decreases with increased experience. There is no need for a special operative or fracture table to perform the procedure. Whether the complication rate is higher with the use of these expensive devices is unknown, but our results demonstrate a 2.2% reoperation rate with the use of the ASI approach performed on a standard OR table. Continued refinement of the technical aspects of ASI-THA may lessen the complication rate

Anterior supine intermuscular total hip arthroplasty (ASI-THA) has emerged as a muscle sparing, less-invasive procedure. The anterior interval is both intermuscular and internervous, providing the advantages of little or no muscle dissection, and a true minimally invasive alternative. It is versatile, with reported use expanding beyond the primary realm to revision and resurfacing THA as well as treatment of acute fracture in elderly patients, who due to their diminished regenerative capacity may benefit more from the muscle-sparing nature of the anterior approach. The ASI approach involves the use of a standard radiolucent operative table with the table extender at the foot of the bed and the patient supine. Fluoroscopy is used in every case. A table-mounted femur elevator is utilised to facilitate femoral preparation. A retrospective review identified 824 patients undergoing 934 consecutive primary ASI-THA performed between January 2007 and December 2010. Age averaged 63.2 years (27–92), BMI averaged 29.9 kg/m2 (16.9–59.2). Gender was 49% males and 51% females. Stem types were short in 82% and standard length in 18%. Follow-up averaged 23.1 months (1–73). Operative time averaged 63.1 minutes (29–143). Blood loss averaged 145.3 minutes (25–1000). Transfusion rate was 3.3% (30 of 914) in single procedures and 80% (8 of 10) in simultaneous bilateral procedures. Length of stay averaged 1.7 days (1–12). Intraoperatively there were 3 calcar cracks and 1 canal perforation treated with cerclage cables. There were 6 wound complications requiring debridement. Four hips had significant lateral femoral cutaneous nerve parathesias not resolved at 12 months. One femoral nerve palsy occurred. At up to 73 months follow-up there have been 21 revisions (2.2%): 2 infection, 1 malpositioned cup corrected same day, 5 metal complications, 2 dislocations, 2 loose cups with one requiring concomitant stem revision secondary to inability to disarticulate trunnion, 1 femoral subsidence and 8 periprosthetic femoral fractures. Primary THA can be safely performed utilising this muscle-sparing approach. We did not see an alarmingly high rate of complications. Instead, rapid recovery and quick return to function were observed. ASI-THA appears to be safe. The recovery advantage utilising this surgical approach is irrefutable. There are complications, most notably periprosthetic femur fracture. The rate, however, appears to be low and decreases with increased experience. There is no need for a special operative or fracture table to perform the procedure. Whether the complication rate is higher with the use of these expensive devices is unknown, but our results demonstrate a 2.2% reoperation rate with the use of the ASI approach performed on a standard OR table. Continued refinement of the technical aspects of ASI-THA may lessen the complication rate

Purpose: The objective of this study was to examine the relationship between aspirin and other non-steroidal anti-inflammatory drugs (NSAIDS) on postoperative blood loss following Total Knee Arthroplasty. Methods: We prospectively examined the pre-operative consumption of aspirin and NSAIDS and haematological parameters of 50 consecutive patients undergoing Total Knee Arthroplasty. 22 (44%) patients were on aspirin only, 17 (34%) patients on aspirin and another NSAID and 11 (22%) patients were taking neither aspirin nor a NSAID. (All patients received 150mg of aspirin the evening before surgery as DVT prophylaxis). Results: The average pre-operative haemoglobin of the group taking aspirin and a NSAID, aspirin only and neither aspirin nor NSAID group was 12.9g/dl, 13,8g/dl and 13.49g/dl respectively. The drop between their pre-operative level and Day 3 Haemoglobin level was 3.788g/dl, 4.45g/dl and 4.28g/dl respectively. The same trend was reflected in the PCV drops of 0.111, 0.133 and 0.1273 respectively. Transfusion rates for the three groups showed that those on aspirin and another NSAID had the highest rate with an average of 0.235 units per patient compared to 0.136 for those on aspirin only and 0.10 for those on neither aspirin nor NSAID. Discussion: These findings indicate that the ingestion of aspirin or a NSAID preoperatively does not increase the amount of blood loss following total knee arthroplasty (TKA). The higher transfusion rates in the aspirin and NSAID group is because of the lower preoperative haemoglobin as compared to the other groups studied. Conclusion: Observation of transfusion trends within our unit has shown a transfusion rate of 18% in patients with a preoperative Haemoglobin level of greater than 13.0g/dl as compared to 48% with a haemoglobin level of 13.0g/dl or less (review of 180 consecutive patients undergoing Total Knee Arthroplasty). The ingestion of aspirin and NSAID does not increase blood loss following TKA but significantly have a lower preoperative Hb level. We feel that pre-operative Haemoglobin levels are the best predictors of transfusion requirements following total knee arthroplasty

Aims

The aim of this study was to examine perioperative blood transfusion practice, and associations with clinical outcomes, in a national cohort of hip fracture patients.

Introduction:. Primary total knee arthroplasty (TKA) is associated with perioperative bleeding, and some patients will require allogenic blood transfusion during their inpatient admission. While blood safety has improved in the last several decades, blood transfusion still carries significant complications and costs. Transfusion indications and alternative methods of blood conservation are being explored. However, there is limited nationally representative data on allogenic blood product utilization among TKA patients, and its associated outcomes and financial burden. The purpose of this study was to use a national administrative database to investigate the trends in utilization and outcomes (i.e. in-hospital mortality, length of stay, admission costs, acute complications) of allogenic blood transfusion in primary TKA patients. Methods:. The Nationwide Inpatient Sample (NIS), the largest all-payer inpatient care database representing a 20% stratified sample of United States hospitals, was utilized. Primary TKA (ICD-9-CM 81.54) cases from 2000 to 2009 were retrospectively queried (n = 4,544,999; weighted national frequency). A total of 67,841 admissions were excluded (Figure 1). The remaining 4,477,158 cases were separated into two study cohorts: (1) patients transfused with allogenic blood products (red blood cells, platelets, serum) (n = 540,270) and (2) patients not transfused (n = 3,936,888). Multivariable regression and generalized estimating equations were used to examine the effect of transfusion on outcomes, adjusting for patient/hospital characteristics and comorbidity. Results:. During the study period, the overall allogenic blood transfusion rate in primary TKA patients was 12.1%. The rate increased ∼5% from 2000 to 2009, and stayed constant around 13% from 2006 to 2009. Transfusion rates were higher in older patients (80–89 yrs, 21.4%; ≥ 90 yrs, 30.7%), blacks (19.6%), females (14.0%), Medicare patients (14.6%), and Medicaid patients (14.4%). Transfused TKA patients had a greater percent of comorbidities than their non-transfused peers. The largest differences in comorbidity prevalence among transfused and non-transfused patients were: deficiency anemia (27.5% vs. 10.1%), renal failure (4.0% vs. 1.4%), chronic blood loss (3.7% vs. 1.4%), and coagulopathy (3.1% vs. 1.0%) (p < 0.001). Unadjusted trends show that from 2000 to 2009, in-hospital mortality rate decreased (Figure 2A), mean length of stay decreased (Figure 2B), and mean admission cost increased (Figure 2C) for both transfused and non-transfused patients following TKA. Adjusting for patient and hospital characteristics, transfused patients had a 22% (95% CI, 4%–43%) greater likelihood of in-hospital mortality (p = 0.013), 0.68 ± 0.02 days longer length of stay (p < 0.001), and $2,237 ± 76 increased admission costs (p < 0.001). Additionally, patients who received a transfusion had a greater adjusted risk of a postoperative infection (odds ratio, 2.35), pulmonary insufficiency (odds ratio, 1.60), and other complications (p < 0.001) (Figure 3). Conclusions:. The allogenic blood transfusion rate increased between 2000 and 2009 in the United States. Transfusion has a considerable burden on patients and healthcare institutions, increasing in-hospital mortality, length of stay, admission costs, and acute complications. Preoperative optimization strategies, transfusion criteria, and hemostatic agents for at-risk patients need to be further researched as possible ways to reduce transfusion occurrence and its effects

The aim of this study is to evaluate techniques which may reduce intra and Post-Operative (PO) bleeding in hip surgery. Methods: In this prospective study, from 9/2005 to 6/2006, we evaluated Blood Loss (BL) after primary total hip arthroplasty. Exclusion criteria were anti-coagulant drugs not discontinued 10 days before surgery and patients whose condition precluded weight bearing PO. We included total hip arthroplasty with posterior surgical approach, spinal anaesthesia, hypotensive surgery and peri-operative blood salvage (Ortho PAS, Euroset). When appropriate, the Mini-Invasive Approach (MIA) was used. In a different sub-set of patients, including some of the minimally invasive patients, a new bipolar Radio-Frequency sealer (TissueLink) was used. The PO program had pain control, LMWH for prevention of DVT, exercise from the day of surgery and walking on crutches from the next day. We analysed: blood loss after surgery and for 3 days; haemoglobin values (g/dL) before surgery and for 5 days PO; thigh circumference pre-op and at 5 days and adverse events such as transfusions and luxation. For the statistical evaluation the paired “t-test” was used, with a level of significance set at 95%. Differences and p values of < 0.05 were considered significant. Results: 324 patients (mean age 68; range 23 to 89; 179 F & 145 M) were admitted to the study. Mean BL was 305ml intraoperative, 501ml at 6 hours PO, 304ml at 1day PO, 132ml at 2 days PO and trace at 3 days. Rather than simple unit measures, we analyzed the Percent Change in Hb from preoperative levels (%CHb). The patients had a mean %CHb of 23,09% at 1day PO, 26,67% at 2 days PO, 28,13% at 3 days and 29,07% at 5 days. Transfusion rates (TR; trigger set at Hb< 8g/dL) were related to the preoperative Hb and age. Overall TR was 15% (51/324), the prevalence of homologous transfusion was 7% (24/324). The TR for each Hb value: 21% (15/69) for Hb=12–13, 20% (20/98) for Hb=13–14, 17% (15/88) for Hb=14–15 and 5% (1/29) for Hb=15–16. The mean value of pain during rehabilitation was 3,11(VAS). MIA (53/324) was associated with reduced BL (mean %CHb at 1st day PO 19.12; TR 9%), but with high variability. The use of bipolar sealer (58/324) was associated with a significant reduction in overall BL (mean %CHb at 1st day PO 15.83; TR 5%) as well as a reduction of thigh swelling (37%) and of mean rehabilitation pain (30%; VAS=2.15). Discussion: Reduced blood loss, reduced post-operative pain and a faster functional resumption are obtained with both the minimally invasive approach and the TissueLink sealer approach. In addition, MIA provides muscle preservation and the use of the TissueLink sealer provides reduced post-operative swelling. Conclusion: This study shows that both the minimally invasive surgical approach and the use of an irrigated RF bipolar sealer can lead to reduced blood loss and faster functional resumption following hip surgery